Martin Tammemagi
Martin Tammemagi
Professor of Epidemiology, Brock University
Verified email at brocku.ca
TitleCited byYear
The national lung screening trial: overview and study design
National Lung Screening Trial Research Team
Radiology 258 (1), 243-253, 2011
7762011
Probability of cancer in pulmonary nodules detected on first screening CT
A McWilliams, MC Tammemagi, JR Mayo, H Roberts, G Liu, K Soghrati, ...
New England Journal of Medicine 369 (10), 910-919, 2013
5432013
Overdiagnosis in low-dose computed tomography screening for lung cancer
EF Patz, P Pinsky, C Gatsonis, JRD Sicks, BS Kramer, MC Tammemägi, ...
JAMA internal medicine 174 (2), 269-274, 2014
4522014
Selection criteria for lung-cancer screening
MC Tammemägi, HA Katki, WG Hocking, TR Church, N Caporaso, ...
New England Journal of Medicine 368 (8), 728-736, 2013
4212013
Targeting of low-dose CT screening according to the risk of lung-cancer death
SA Kovalchik, M Tammemagi, CD Berg, NE Caporaso, TL Riley, M Korch, ...
New England Journal of Medicine 369 (3), 245-254, 2013
3682013
Comorbidity and survival disparities among black and white patients with breast cancer
CM Tammemagi, D Nerenz, C Neslund-Dudas, C Feldkamp, ...
Jama 294 (14), 1765-1772, 2005
3382005
Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the US Preventive Services Task Force
HJ de Koning, R Meza, SK Plevritis, K Ten Haaf, VN Munshi, J Jeon, ...
Annals of internal medicine 160 (5), 311-320, 2014
3042014
Smoking and lung cancer survival: the role of comorbidity and treatment
CM Tammemagi, C Neslund-Dudas, M Simoff, P Kvale
Chest 125 (1), 27-37, 2004
2642004
Impact of comorbidity on lung cancer survival
CM Tammemagi, C Neslund‐Dudas, M Simoff, P Kvale
International journal of cancer 103 (6), 792-802, 2003
2472003
Lung cancer risk prediction: prostate, lung, colorectal and ovarian cancer screening trial models and validation
CM Tammemagi, PF Pinsky, NE Caporaso, PA Kvale, WG Hocking, ...
Journal of the national cancer institute 103 (13), 1058-1068, 2011
2122011
Evaluation of the lung cancer risks at which to screen ever-and never-smokers: screening rules applied to the PLCO and NLST cohorts
MC Tammemägi, TR Church, WG Hocking, GA Silvestri, PA Kvale, ...
PLoS medicine 11 (12), e1001764, 2014
1372014
Interstitial lung abnormalities in a CT lung cancer screening population: prevalence and progression rate
GY Jin, D Lynch, A Chawla, K Garg, MC Tammemagi, H Sahin, S Misumi, ...
Radiology 268 (2), 563-571, 2013
1162013
Impact of lung cancer screening results on smoking cessation
MC Tammemägi, CD Berg, TL Riley, CR Cunningham, KL Taylor
JNCI: Journal of the National Cancer Institute 106 (6), 2014
1122014
Long-term prognostic role of functional limitations among women with breast cancer
D Braithwaite, WA Satariano, B Sternfeld, RA Hiatt, PA Ganz, ...
Journal of the National Cancer Institute 102 (19), 1468-1477, 2010
1082010
In lung cancer patients, age, race-ethnicity, gender and smoking predict adverse comorbidity, which in turn predicts treatment and survival
CM Tammemagi, C Neslund-Dudas, M Simoff, P Kvale
Journal of clinical epidemiology 57 (6), 597-609, 2004
1082004
Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers
MC Tammemagi, JR McLaughlin, SB Bull
Cancer Epidemiology and Prevention Biomarkers 8 (7), 625-634, 1999
1061999
Hypertension is an independent predictor of survival disparity between African‐American and white breast cancer patients
D Braithwaite, CM Tammemagi, DH Moore, EM Ozanne, RA Hiatt, ...
International Journal of Cancer 124 (5), 1213-1219, 2009
1022009
Identification of 14-3-3𝛉 as an Antigen that Induces a Humoral Response in Lung Cancer
SR Pereira-Faca, R Kuick, E Puravs, Q Zhang, AL Krasnoselsky, ...
Cancer Research 67 (24), 12000-12006, 2007
882007
p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival.
AG Casson, M Tammemagi, S Eskandarian, M Redston, J McLaughlin, ...
Molecular Pathology 51 (2), 71, 1998
851998
Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma
P Wheatley-Price, B Yang, D Patsios, D Patel, C Ma, W Xu, N Leighl, ...
Journal of clinical oncology 28 (20), 3316-3322, 2010
842010
The system can't perform the operation now. Try again later.
Articles 1–20